UK HealthCare

Funding Applications for Cervical Cancer-Free Kentucky Mini-Awards Due August 1


LEXINGTON, Ky. (June 17, 2011) − Cervical Cancer-Free Kentucky (CCFKY), housed at the University of Kentucky College of Public Health, is accepting applications for funding awards to be allocated to local agencies, coalitions, community groups and organizations to develop and disseminate novel strategies to improve HPV and cervical cancer screening rates.  

Support at two funding levels -- $10,000 and $20,000 -- will be awarded to approximately 10 innovative projects to help reduce cervical cancer incidence and mortality in Kentucky. Despite the fact that cervical cancer is largely preventable, annually about 391 women develop cervical cancer in Kentucky, and 66 women die. 

“We hope that these mini-awards will help call attention to the need for creative strategies to eliminate cervical cancer by enhancing the work of grassroots community-based organizations and local lead agencies in Kentucky,” said Dr. Baretta R. Casey, director of CCFKY.  “Together we can improve HPV vaccination, screening, and eradicate deaths from cervical cancer in our lifetime.  No one should die from this preventable and curable disease.”

Detailed instructions for the mini-award application may be found on the CCFKY website: Funds may be used for research supplies, participant compensation (incentives), printing and media expenses, staff salary and consultant fees, meeting and training expenses for non-health care professionals (see restrictions noted in the application) and in-state travel related to the project.  Examples of previously funded Mini-Award reports are located on the website:  To get involved and for more information on Cervical Cancer-Free Kentucky, visit

About Cervical Cancer-Free Kentucky

Cervical Cancer-Free America is a state-wide initiative supported by an unrestricted gift from Glaxo-Smith-Kline. CCFKY is implementing a broad public health strategy to eliminate cervical cancer through vaccination and effective screening. For more information, please visit